BTIG analyst Sean Lavin maintained a Hold rating on Intersect ENT (NASDAQ: XENT) yesterday. The company’s shares opened today at $37.20.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 15.1% and a 63.0% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Boston Scientific Corp.
Currently, the analyst consensus on Intersect ENT is Moderate Buy and the average price target is $40.75, representing a 9.5% upside.
In a report issued on May 2, Northland Securities also maintained a Hold rating on the stock with a $32 price target.
Find more picks by Best Performing Analysts >>
Based on Intersect ENT’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $6.14 million. In comparison, last year the company had a GAAP net loss of $6.68 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intersect ENT, Inc. is a medical technology company, which is dedicated in the treatment of ear, nose, and throat conditions through evidence-based innovation, providing physicians with solutions to improve quality of life for patients. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.
